Schließen
HIV Life Cycle
Classes of Drugs in Clinical Use
2 Drug Regimen
Post Exposure Prophylaxis (PEP)
3 Drug Regimens
Post Exposure Prophylaxis (PEP)
Nucleoside and nucleotide reverse transcriptase (NRTIs) inhibitors
Drug Examples
Nucleoside and nucleotide reverse transcriptase (NRTIs) inhibitors
Zidovudine, Lamivudine
Information
Nucleoside and nucleotide reverse transcriptase (NRTIs) inhibitors
Adverse Drug Reactions
First anti-HIV drug approved
Non-nucleoside reverse transcriptase Inhibitors (NNTRIs)
Examples
Non-nucleoside reverse transcriptase Inhibitors (NNTRIs)
MOA
Non-nucleoside reverse transcriptase Inhibitors (NNTRIs)
Adverse Reactions
Non-nucleoside reverse transcriptase Inhibitors (NNTRIs)
Metabolism
Protease Inhibitors (PIs)
Examples
Protease Inhibitors (PIs)
MOA
Protease Inhibitors (PIs)
Adverse Effects
Entry Inhibitors
Example
Entry Inhibitors
MOA
Entry Inhibitor
Delivery
Entry Inhibitors
Adverse Effects
Integrase Inhibitors
Example
Integrase Inhibitors
MOA
Investigational Agents
Bevirimat, TNX-355
Antiretroviral Therapy
Guidelines
Conditions during which
Antiretroviral Therapy
should always be initiated
regardless of CD4 count
Highly Active
Anti-Retroviral Therapy (HAART)
Initial Regimine
Highly Active
Anti-Retroviral Therapy (HAART)
Treatment Goals
Highly Active
Anti-Retroviral Therapy (HAART)
Suggested Combos and Restrictions
